SpringWorks Therapeutics reports Q1 EPS ($1.18), consensus ($1.18)

Reports Q1 revenue $21.0M, consensus $12.21M. “We are very encouraged by the strong start to the OGSIVEO launch and are focused on continuing our momentum towards establishing OGSIVEO as the standard of care treatment for adults with desmoid tumors,” said CEO Saqib Islam. “We are also pleased to have initiated the rolling NDA submission for mirdametinib in children and adults with NF1-PN, which would be our second marketed product serving another group of patients who are currently suffering with a high unmet need, if approved. We are making significant progress across our commercial, development and corporate objectives and look forward to providing updates throughout the year.”